These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9257770)

  • 1. In vitro activity of Bay 12-8039, a new 8-methoxyquinolone.
    Fass RJ
    Antimicrob Agents Chemother; 1997 Aug; 41(8):1818-24. PubMed ID: 9257770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes.
    Aldridge KE; Ashcraft DS
    Antimicrob Agents Chemother; 1997 Mar; 41(3):709-11. PubMed ID: 9056020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of the new quinolone moxifloxacin (Bay 12-8039) against resistant gram-positive clinical isolates.
    Alcalá L; Cercenado E; García-Garrote F; Bouza E
    Diagn Microbiol Infect Dis; 1999 Jan; 33(1):27-31. PubMed ID: 9990472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae.
    Roblin PM; Hammerschlag MR
    Antimicrob Agents Chemother; 1998 Apr; 42(4):951-2. PubMed ID: 9559818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bay 12-8039, a new 8-methoxy-quinolone: comparative in-vitro activity with nine other antimicrobials against anaerobic bacteria.
    MacGowan AP; Bowker KE; Holt HA; Wootton M; Reeves DS
    J Antimicrob Chemother; 1997 Oct; 40(4):503-9. PubMed ID: 9372419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.
    Bauernfeind A
    J Antimicrob Chemother; 1997 Nov; 40(5):639-51. PubMed ID: 9421311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of BAY 12-8039, a new fluoroquinolone.
    Woodcock JM; Andrews JM; Boswell FJ; Brenwald NP; Wise R
    Antimicrob Agents Chemother; 1997 Jan; 41(1):101-6. PubMed ID: 8980763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracellular activity of ciprofloxacin and moxifloxacin, a new 8-methoxyquinolone, against methicillin-resistant Staphylococcus aureus.
    Al-Nawas B; Shah PM
    J Antimicrob Chemother; 1998 Jun; 41(6):655-8. PubMed ID: 9687105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin.
    Pong A; Thomson KS; Moland ES; Chartrand SA; Sanders CC
    J Antimicrob Chemother; 1999 Nov; 44(5):621-7. PubMed ID: 10552978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of Bay 12-8039, a new 8-methoxyquinolone, compared to the activities of 11 other oral antimicrobial agents against 390 aerobic and anaerobic bacteria isolated from human and animal bite wound skin and soft tissue infections in humans.
    Goldstein EJ; Citron DM; Hudspeth M; Hunt Gerardo S; Merriam CV
    Antimicrob Agents Chemother; 1997 Jul; 41(7):1552-7. PubMed ID: 9210683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone.
    Dalhoff A; Petersen U; Endermann R
    Chemotherapy; 1996; 42(6):410-25. PubMed ID: 8957575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of Bay y 3118, a new quinolone.
    Fass RJ
    Antimicrob Agents Chemother; 1993 Nov; 37(11):2348-57. PubMed ID: 8285618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of moxifloxacin, a new 8-methoxyquinolone, against gram-positive bacteria.
    Malathum K; Singh KV; Murray BE
    Diagn Microbiol Infect Dis; 1999 Oct; 35(2):127-33. PubMed ID: 10579093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of gatifloxacin compared with gemifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens cultured from patients with complicated urinary tract infections.
    Naber KG; Hollauer K; Kirchbauer D; Witte W
    Int J Antimicrob Agents; 2000 Nov; 16(3):239-43. PubMed ID: 11091042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990.
    Bauernfeind A
    J Antimicrob Chemother; 1993 Apr; 31(4):505-22. PubMed ID: 7605398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipneumococcal activity of BAY 12-8039, a new quinolone, compared with activities of three other quinolones and four oral beta-lactams.
    Visalli MA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1997 Dec; 41(12):2786-9. PubMed ID: 9420061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro activity of moxifloxacin against fluoroquinolone-resistant strains of aerobic gram-negative bacilli and Enterococcus faecalis.
    Tankovic J; Bachoual R; Ouabdesselam S; Boudjadja A; Soussy CJ
    J Antimicrob Chemother; 1999 May; 43 Suppl B():19-23. PubMed ID: 10382871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concentration-dependent killing of antibiotic-resistant pneumococci by the methoxyquinolone moxifloxacin.
    Klugman KP; Capper T
    J Antimicrob Chemother; 1997 Dec; 40(6):797-802. PubMed ID: 9462430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates.
    Kowalski RP; Dhaliwal DK; Karenchak LM; Romanowski EG; Mah FS; Ritterband DC; Gordon YJ
    Am J Ophthalmol; 2003 Sep; 136(3):500-5. PubMed ID: 12967804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of BAY 12-8039, a new fluoroquinolone against mycoplasmas.
    Bébéar CM; Renaudin H; Boudjadja A; Bébéar C
    Antimicrob Agents Chemother; 1998 Mar; 42(3):703-4. PubMed ID: 9517957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.